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Myopathy with anti-HMGCR antibodies
Perimysium and myofiber pathology
ABSTRACT
Objective: To analyze clinical features and myopathology changes in muscle fibers, connective
tissue, and vessels in 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibody–
associated myopathies.
Methods: Retrospective review of records and myopathologic features of 49 consecutive pa-
tients with myopathies and serum HMGCR antibodies.
Results: Clinical features included onset age from 12 to 83 years, female predominance (67%),
proximal, symmetric weakness (84%), muscle discomfort (78%), dysphagia (35%), systemic fea-
tures, including skin rash and interstitial lung disease (37%), statin use (38%), and a high serum cre-
atine kinase (83%).Myopathology includedmuscle fiber necrosis or regeneration (66%), myonuclear
pathology (43%), perimysial connective tissue damage (61%), and lymphocytic foci (27%).
Conclusions: Patients with HMGCR antibody–associated myopathies present with weakness and
muscle discomfort and often have damage to both perimysial connective tissue andmuscle fibers, with
necrosis and myonuclear pathology. Only a minority of patients with HMGCR antibody–associated
myopathies have a history of statin exposure. Neurol Neuroimmunol Neuroinflamm 2015;2:e124;
doi: 10.1212/NXI.0000000000000124
GLOSSARY
CK5 creatine kinase; HMGCR5 3-hydroxy-3-methylglutaryl-coenzyme A reductase; IIM5 immune and inflammatory myop-
athy; IMPP 5 immune myopathies with perimysial pathology; MHC 5 major histocompatibility complex; NGS 5 normal goat
serum; PBS 5 phosphate-buffered saline.
Serum autoantibodies and myopathology features are useful for characterization and classifica-
tion of acquired immune and inflammatory myopathy (IIM) syndromes.1–3 Serum IgG binding
to 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) has been identified in patients
with presumed immune myopathies that usually have no lymphocytic cell foci.4,5 Myopathies
with HMGCR antibodies have been suggested to be statin-induced, but statin histories are not
universal and the strength of association with statin use varies among reports.5–10
Previous pathologic descriptions of myopathies with HMGCR antibodies have noted active
necrosis and regeneration of scattered muscle fibers without inflammation,5 but some series mainly
screened for HMGCR antibodies in groups of patients with “necrotizing myopathies.”6 Involvement
of other components of muscle tissue has not been systematically evaluated.We have found that IIM
syndromes often have characteristic pathology that involves several tissues in muscle, including
muscle fibers, connective tissue, and vessels, and patterns of humoral and cellular immunity.3 In
this study we evaluated clinical and pathologic features of 49 patients with acquired myopathies
associated with serum IgG binding to HMGCR. Clinically, our patients had symmetric, proximal
weakness and often had a high serum creatine kinase (CK). Only a minority had a history of statin
use. Pathologic features in HMGCR antibody–associated myopathies often include damage to both
perimysial connective tissue and muscle fibers.
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METHODS Patients. We retrospectively analyzed charts, lab-
oratory records, and muscle biopsies from 49 patients with high
levels of serum HMGCR antibodies (titers . 2,800). Muscle
biopsies of 44 patients were evaluated at Washington University
School of Medicine in Saint Louis. The presence and degree of
myonuclear pathology were evaluated later by 2 different pathol-
ogists (A.P. and A.A.) in 40 available muscle biopsies. We tested
37 additional sera from patients with a definite diagnosis of inclu-
sion body myositis.11
Standard protocol approvals, registrations, and patient
consents. The Human Studies Committee of Washington Uni-
versity in Saint Louis approved all procedures.
Histochemical and immunohistochemical evaluation.
Cryostat sections of rapidly frozen muscle were processed using
the same methodology described in our previous studies.12,13
Immunohistochemical stains for antibodies were performed on
consecutive sections using muscle from patients and paired con-
trols on the same glass slide. Primary antibodies used in this study
were directed against HAM-56 (macrophages), CD8, CD4, CD20,
C5b-9 complement (membrane attack complex) (Sigma-Aldrich,
St. Louis, MO), and class I human major histocompatibility
complex (MHC) (US Biological, Swampscott, MA). Ulex
Europaeus Agglutinin I lectin (Sigma-Aldrich) was used to
visualize endothelium in vessels.
Anti-HMGCR ELISA. HMGCR antigen (Sigma-H7039)
(Sigma-Aldrich) was diluted to 2 mg/mL in 0.01 M
phosphate-buffered saline (PBS). HMGCR 0.1 mg was
placed in each well of Immulon 2 HB ELISA plates
(Thermo Fisher Scientific, Waltham, MA) and incubated
overnight at 4°C. After washing 3 times with PBS-0.05%
Tween 20, residual nonspecific binding sites in ELISA wells
were blocked with 1% normal goat serum in PBS (PBS-NGS)
(100 mL per well) for 4 hours at room temperature and washed
3 times with PBS-NGS. Subsequent steps were performed at
4°C. Between steps, washing was performed 5 times using
PBS-NGS without detergent. Patient sera were tested in
duplicate at 1:3,000 dilution with overnight incubation in
ELISA wells at 4°C. Binding of serum IgG to HMGCR was
measured using a 4-hour exposure to goat anti-human IgG
linked to horseradish peroxidase (Organon Teknika–Cappel,
West Chester, PA) in PBS with 1% bovine serum albumin
(1:20,000). Color was developed with 100 mL substrate
buffer (0.1 M citrate buffer, pH 4.5 with 0.004% H2O2
and 0.1% phenylenediamine) for 30 minutes. Optical
density was measured at 450 nm. Final anti-HMGCR
antibody titers were calculated after subtracting levels of
nonspecific serum IgG binding to sulfatide. A normal range
of values was determined by analysis of sera from 85 adult
patients with other immune or inflammatory neuromuscular
disorders.
Statistical analysis. Fisher exact test was used to compare cate-
gorical variables. Independent 2-tailed t test and mean 6
standard error were used to compare and report quantitative
Figure 1 Muscle biopsy from a patient with a slowly progressive (24 years) HMGCR antibody–associated
myopathy syndrome
(A) Hematoxylin & eosin stain, (B) Verhoeff-van Gieson stain. Muscle fiber size varies from very small to hypertrophied. Some
small muscle fibers have mildly basophilic, or darkly stained, cytoplasm (white arrows). A few muscle fibers have internal
nuclei. Endomysial connective tissue between muscle fibers is increased. (C) Alkaline phosphatase stains perimysial con-
nective tissue and the cytoplasm of scattered small muscle fibers (white arrow). (D) Acid phosphatase stains scattered cells
in the perimysium and cells associatedwith a necroticmuscle fiber (black arrow). Scale bar550mMfor A, B, andDand100mM
for C. HMGCR 5 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
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variables. A p value, 0.05 was considered a significant difference
between groups.
RESULTS Case report. A 26-year-old woman noted
proximal weakness with onset shortly after the
delivery of her first child that progressed over a few
months to difficulty walking up and down stairs.
There was no history of statin use or dyspnea.
Examination showed symmetric, mild proximal
weakness but no skin rash. Laboratory testing
showed a myopathic EMG, a serum CK of 6,270
IU/L, and an antinuclear antibody titer of 1:320.
Muscle biopsies (figure 1) at presentation and
8 years later showed increased endomysial connective
tissue, many small- and moderate-sized basophilic
muscle fibers, scattered necrotic fibers, and no foci of
lymphocytic inflammation. Alkaline phosphatase
diffusely stained the perimysium (figure 1C).
Dystrophy-related protein staining and blots were
normal for dystrophin, sarcoglycans, a-dystroglycan,
dysferlin, desmin, emerin, calpain-3, caveolin-3, and
laminin-a2. Gene testing was not performed. Oral
treatments with high-dose prednisone, methotrexate,
cyclosporine, and azathioprine produced no functional
benefit. Myositis-specific antibody panels were negative
on several occasions. Anti-HMGCR antibody titers
were 34,000 in a serum sample obtained in 1991 and
48,000 in 2013. Weakness was slowly progressive.
Twenty-three years after disease onset she required a
scooter for mobility and could only walk 3 m with
help. Quantitative testing showed strength that was
50%–60% of normal in proximal muscles in the
arms and legs and normal in distal muscles.
HMGCR antibodies. HMGCR antibody titers in our
initial 49 patients ranged from 2,800 to 80,000. In
the few patients with serial sera available, as in our case
report, antibody titers showed no clear changes over
long periods of time. A second patient evaluated over
a very long period had titers of 7,000 at presentation,
which included rapidly progressive severe weakness with
respiratory failure, and 12,000 7 years later after chronic
corticosteroid treatment that was associated with
improvement to near-normal strength.












Clinical symptoms & signs
Statin exposure 18/47 (38)
Weakness, proximal 41/49 (84)
Muscle discomfort 38/49 (78)
Dysphagia 17/49 (35)
Skin rash 12/49 (25)
Dyspnea 15/49 (31)
Interstitial lung disease 10/49 (20)
Malignancy history 5/49 (10)
Laboratory results
Serum CK, mean 6 SE (%
high)
4,232 6 874 (83)
Serum aldolase, mean 6 SE
(% high)
38 6 8 (75)
HMGCR antibody titers, mean
6 SE
12,606 6 2,367
ANA > 1:80 11/49 (23)












Immaturity & regeneration 29/44 (66)
Class I MHC upregulation
(diffuse)
12/40 (30)






Acid phosphatase & HAM56
cells
20/44 (45)
Mononuclear cells 20/44 (45)





Mononuclear cell foci 12/44 (27)
B cells in foci 7/44 (16)
Abbreviations: ANA 5 antinuclear antibody; CK 5 creatine
kinase; HMGCR 5 3-hydroxy-3-methylglutaryl-coenzyme A
reductase; MHC 5 major histocompatibility complex.
Data are n/N (%), unless otherwise indicated.
aSignal recognition particle (#1), PM-Scl (#3), RNP (#5), Ku
(#2), and SSA (#2).
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Clinical characteristics. Patients with HMGCR anti-
bodies included 33 females (67%) and 16 males
(33%) (table). Mean age at disease onset was 50 years
(range 12–83 years). Ethnicities were Caucasian
(76%), African American (22%), and Asian (2%).
Neuromuscular symptoms included myalgia (78%)
and dysphagia (35%). Weakness was present on
examination in 84%. The 8 patients (16%) with no
weakness reported muscle discomfort, cramps, or fas-
ciculations. On examination, weakness was generally
symmetric (98%) and proximal-greater-than-distal
(100%). The course of disease progression ranged
from subacute (progression to respiratory failure over
2 months) to chronic (slow progression over decades
mimicking limb-girdle muscular dystrophies; see case
report). Systemic features (37%) included skin rash
affecting the face, chest, and dorsum of the hands
(22%); interstitial lung disease (by chest imaging)
(20%); and associated malignancy (10%) (pancreatic
[2], colon, prostate, and hematologic). Statin use was
reported in 38% of patients. Statin users were older
(p 5 0.005; mean 58 years) than nonusers (mean
44 years). The frequency of a history of statin use in
our cohort was somewhat higher than, but not
statistically different from, patients in an age-matched
concurrent group with other immune myopathies
(38% vs 23%; p 5 0.2). There were no differences
in any clinical features between patients with or
without statin exposure (table).
Laboratory data. Anti-HMGCR antibody titers ranged
from 2,800 to 80,000 (mean 12,606) and were sim-
ilar in patients with and without statin exposure
(table). Serum CK was high in 83% of our patients
(mean 4,232 IU/L; range 26 to 27,000). Fifty percent
of patients with normal strength had high serum CK
(mean 447 IU/L; range 48–1,846). Patients with very
high titers of anti-HMGCR antibodies ($6,000) had
higher levels of serum CK (p 5 0.006). Serum
aldolase was high in 75% (mean 38 U/L; range
3.9–291). Three patients with normal serum CK
levels had a high aldolase. Other serum antibodies
included antinuclear (22%), anti-synthetase (18%
[Jo-1, 14%]), signal recognition particle (2%), and
connective tissue disease overlap antibodies (PM-
Scl, SSA, or RNP) (16%). EMG was often
myopathic (74%), with fibrillation potentials and/or
positive sharp waves in many (65%).
Myopathology. Common myopathic features involved
muscle fibers and perimysial connective tissue (table;
figures 1–3). Muscle fiber pathology included evidence
of ongoing damage, with fibers in varied stages of
necrosis (52%) and regeneration or immaturity
(66%) (figure 1). C5b-9 complement stained the cyto-
plasm of some necrotic muscle fibers but was not typ-
ically deposited on the surface of non-necrotic muscle
fibers. Large clusters of contiguous damaged fibers were
not present. In some muscles, immature fibers and
necrosis were most prominent at the edge of fascicles
near damaged or cellular perimysial connective tissue
(figure 3, C and F). Focal invasion of muscle fibers by
cells was present in a few patients (7%). Myonuclear
pathology (43%) (figure 2) included enlargement,
irregular shapes, empty central regions, and clusters.
Perimysial connective tissue pathology was present in
61% of biopsies, with diffuse alkaline phosphatase
staining (figure 1C), histiocytic (acid phosphatase-
and esterase-positive) cells (figure 3, B and E), or
damaged structure (figure 3D). The most common
general pathologic pattern (57%; 25/44) was for both
muscle fiber and perimysial pathology to be present.
Muscles with neither muscle fiber nor perimysial
pathology occurred in 25% (11/44). Weakness was
more common (p 5 0.017) in patients with
perimysial damage (100%) than in those without
perimysial damage (77%). Anti-HMGCR antibody
titers were higher in patients with muscle biopsies
showing muscle fiber necrosis (19,748 6 4,509 vs
6,538 6 1,249; p 5 0.001) and connective tissue
damage (17,841 6 3,998 vs 6,459 6 1,027; p 5
0.03). Some biopsies contained lymphocytic cell foci
(27%), generally surrounding intermediate-sized
perimysial vessels. MHC class I was diffusely
upregulated by all muscle fibers in some biopsies
(30%). In some cases MHC class I expression was
Figure 2 Abnormal myofiber nuclei in HMGCR antibody–associated myopathy
Myonuclei are often enlarged (dark arrow) with clear centers (dark arrowhead) or irregular
shapes (light arrowhead). Internal nuclei are common. Some myonuclei are in abnormal clus-
ters or clumps (light arrows). Scale bar 5 18 mM. HMGCR 5 3-hydroxy-3-methylglutaryl-
coenzyme A reductase.
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more prominent on fibers at the edge of fascicles near
perimysium. There were no differences in biopsy
features between patients with or without statin use.
Endomysial connective tissue was increased in a few
biopsies (8%), mostly in patients with longer histories
of disease (figure 1). Vacuoles in muscle fibers were not
observed.
HMGCR antibodies in patients with inclusion body
myositis. To evaluate the specificity of HMGCR anti-
bodies for the myopathologic features identified in
this study, we tested sera from 37 patients with
definite inclusion body myositis, a group in whom
we did not expect to detect positive results. We found
2 sera with high HMGCR antibody titers (2,900 and
8,400). Both patients also had serum IgG binding to
NT5C1A antigen. The muscle pathology in these 2
patients showed changes consistent with inclusion
body myositis, including vacuoles containing baso-
philic debris, endomysial foci of CD4 and CD8 lym-
phocytes with focal invasion of muscle fibers, and
diffuse upregulation of MHC class I by muscle fibers.
However, there were also scattered necrotic muscle
fibers and perimysial connective tissue pathology
(alkaline phosphatase staining and acid phospha-
tase–positive cells), as noted above in other HMGCR
antibody–positive patients. Similar changes were found
in only 2 of the 35 HMGCR antibody–negative
inclusion body myositis patients (p 5 0.008).
DISCUSSION We retrospectively reviewed clinical
and myopathology features of 49 patients with serum
anti-HMGCR antibodies. Some clinical features in
our patients with serum IgG binding to HMGCR
Figure 3 Perimysial and muscle fiber pathology in HMGCR antibody–associated myopathy
(A) Perimysial pathology with histiocytic cells and widening (hematoxylin & eosin stain). (B) Most cells in the perimysium are
histiocytic and stain for acid phosphatase. (C) Muscle fibers at the edge of some fascicles are small and may be dark-stained
(immature) (nicotinamide adenine dinucleotide stain). (D) Fragmentation of perimysial connective tissue (Gomori trichrome
stain). (E) Cells in perimysial connective tissue are scattered, large, and irregularly shaped (nonspecific esterase stain).
(F) Necrotic (dark) muscle fibers, with C5b-9 complement staining of cytoplasm, are scattered through the muscle but
may have increased frequency at the edge of fascicles, a feature common in immune myopathies with perimysial pathology.
C5b-9 complement is also deposited in perimysial connective tissue, occasionally extending into the endomysium. Scale
bar 5 100 mM for A, B, and D and 50 mM for C, E, and F. HMGCR 5 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
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were similar to those in previous studies.5,6 We observed
a moderate female predominance. Onset ages varied
widely from childhood to older adulthood. Presenting
features often included proximal, symmetric weakness,
myalgia, and a high serum CK. The disease course
varied from acute to very chronic. Three patients with
slowly progressive proximal weakness were initially
thought to have limb-girdle muscular dystrophies but
had no histologic or molecular diagnosis despite
extensive testing. Patients with previous exposure to
statin drugs were older, but clinical and laboratory
findings were similar to those in patients without
statin exposure.
Differences in our cohort from prior studies
included a small group of HMGCR antibody patients
who presented with myalgia, cramps, and elevated
CK but no weakness.14,15 Systemic manifestations,
including skin rash and interstitial lung disease, were
more frequent than previously reported. Interstitial
lung disease, ascertained by chest imaging, was found
in 20% of our cohort. Other myositis-associated anti-
bodies were identified in 33% of our patients. The
wider spectrum of clinical and laboratory features
seen in our series likely reflects our inclusive pattern
of serum testing (i.e., most patients with acquired
myopathies). The initial series of HMGCR antibody
patients excluded patients with inflammation in the
muscle biopsy and selectively studied patients referred
to a myositis clinic.4 Another series analyzed only
patients who had noninflammatory biopsies with
active and prominent muscle fiber necrosis and
regeneration.6
Our data suggest that myopathies associated with
HMGCR antibodies should not be called “statin
myopathies.” Statin-intolerant patients with a clear
temporal association between statin intake and symp-
toms have a very low frequency of HMGCR anti-
bodies.14 In all but one study, a substantial
proportion of HMGCR antibody–positive patients
(37% to 62%) have been statin-naive.5,6,16 In some
HMGCR antibody–positive patients, the statin expo-
sure was years prior to the onset of myopathy. An
Australian report is an outlier, finding that 94% of
HMGCR antibody–positive patients had statin expo-
sure.9 In this study the clinical correlations, including
myopathy type and sex predominance, also differed
from other reports.
The initial focus of our study was to analyze the
myopathology features of HMGCR antibody pa-
tients. Our results show that 2 components of muscle
tissue are commonly involved: muscle fibers and con-
nective tissue. Muscle fibers showed 2 patterns of
pathology. Non-necrotic muscle fibers often had
nuclear pathology with irregular shapes, enlargement,
and aggregation (figure 2). This pattern of myopa-
thology of uncertain cause is not common in most
other myopathies with prominent necrosis. A study of
myopathies associated with Jo-1 antibodies found
nuclear actin aggregates in many patients.17 The rela-
tionship between these nuclear aggregates and the
myonuclear pathology seen on histologic sections in
our study is unclear because ultrastructural analysis
was not available. A second pattern of myofiber
pathology is the scattered fibers in different stages
of necrosis and regeneration that has been described
in all previous studies of HMGCR antibody patients.
This general pattern of scattered, ongoing muscle
fiber necrosis is not specific for HMGCR antibody
syndromes and is common in many immune and
hereditary myopathies.18 One distinctive feature of
the distribution of the muscle fiber necrosis in some
of our HMGCR antibody patients was a tendency for
necrotic and regenerating fibers to be more common
at the edge of fascicles near the perimysium. This
distribution of necrosis occurs in immune myopathies
with perimysial pathology (IMPP), such as those seen
with Jo-1 antibodies.12,17 The patterns of scattered
necrosis differ from the clusters of muscle fibers in
similar stages of necrosis seen in regional ischemic
immune myopathy, which is likely due to vascular
pathology.19
The second area of muscle commonly involved in
HMGCR antibody patients is connective tissue, espe-
cially the perimysium. Perimysial pathology with
scattered histiocytic cells, alkaline phosphatase stain-
ing, and damaged structure (figures 1 and 3) was as
common as muscle fiber necrosis in our HMGCR
antibody patients. HMGCR antibody–associated
myopathology is similar to disorders in the IMPP
pathologic group.3 Damage to both perimysial con-
nective tissue and muscle fibers is the most common
pattern of myopathology in IMPP, Jo-1 antibody–
associated myopathies, and our HMGCR patients.
The common types of muscle fiber damage in IMPP
syndromes are necrosis and regeneration, which are
more prominent in perifascicular regions near peri-
mysium and nuclear pathology.3,12,17 There is also
some clinical overlap of features between IMPP syn-
dromes and our patients. Systemic features present in
37% of our patient series included interstitial lung
disease or a skin rash.
Our myopathology results differ from previous de-
scriptions of HMGCR patients, which have mainly
emphasized the myopathy as “necrotic.”5,6,9,10 One
reason for this discrepancy is that some studies have
biased their results by selecting patients based on the
presence of muscle fiber necrosis. Another issue
reducing reporting of perimysial damage may be that
our pathology laboratory routinely performs histo-
chemical analysis of muscle biopsies that includes acid
and alkaline phosphatase stains. Acid and alkaline
phosphatase stains are especially sensitive for
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observing cellular and molecular pathology in peri-
mysial connective tissue.3 They are not routinely per-
formed in many laboratories and were not reported in
previous HMGCR series.
The specificity of HMGCR antibodies in immune
and other myopathies requires further study. One series
reported that HMGCR antibodies occur in 10% of pa-
tients with an entirely different disorder, inclusion body
myositis.9 Our initial results, identifying 49 antibody-
positive patients, were at least partly the result of clini-
cians with a suspicion of an HMGCR antibody–associ-
ated syndrome ordering serum testing. Our follow-up
review of patients diagnosed with inclusion body myo-
sitis suggested a prevalence of 5.4%. However, review of
the muscle biopsies in the 2 positive patients showed
perimysial connective tissue damage in addition to the
typical inclusion body myositis pathology. It is well-
known that there is an increased frequency of associated
immune features in inclusion body myositis, including
antinuclear antibodies, SSA, and M proteins.20,21 Clin-
ically, the patients had features that were somewhat
atypical for inclusion body myositis, including younger
onset in the fifth decade and prominent proximal weak-
ness early in the disease course. This suggests that these
patients may have had 2 concurrent myopathy syn-
dromes, inclusion body myositis and HMGCR anti-
body–associated myopathology. HMGCR antibodies
may correlate better with specific pathology features
than with general clinical diagnoses.
HMGCR antibody–associated myopathies can be
considered in the context of the common clinical
classification and our proposed pathologic groups of
immune myopathies.3 Polymyositis and inclusion
body myositis can be ruled out because there are
few lymphocytic inflammatory foci or inclusion bod-
ies in HMGCR myopathies. Dermatomyositis is not
a useful diagnosis because skin changes were present
in only a minority of our patients. Necrotic myopa-
thies are a possible class within which to group
HMGCR patients, but such a classification is mis-
leading and lacks pathologic specificity. The term
“necrotic myopathy” can be applied equally well to
rhabdomyolysis and a variety of hereditary, ischemic,
and toxic disorders.18 Denoting the HMGCR syn-
drome as a necrotic myopathy implies that myofiber
necrosis is a constant feature and that the disorder
involves mainly damage to muscle fibers. However,
connective tissue in perimysium is also commonly
damaged in HMGCRmyopathies. The connective tis-
sue damage includes distinctive cellular mechanisms
with histiocytic, not lymphocytic, infiltration. In
muscles in which necrosis is present, the myopathic
features are often nonuniform and more prominent
near the perimysium. An additional non-necrotic mus-
cle fiber pathology, abnormal myonuclear morphol-
ogy, was also observed in many biopsies.
The therapeutic response of some patients with
HMGCR antibodies to immunomodulation supports
the idea that these myopathies are autoimmune disor-
ders.4,6,22 The absence of lymphocytic inflammation
suggests that humoral mechanisms may be important.
However, despite the presence of serum autoantibodies,
intracellular molecules such as HMGCR have been dif-
ficult to implicate as pathogenic target antigens of
humoral or cellular immune mechanisms in immune
disorders. The specific molecular antigenic targets of
the immune response in muscle and connective tissue
in HMGCR antibody–associated myopathy remain to
be defined.
AUTHOR CONTRIBUTIONS
Ali Alshehri: obtaining, analysis, and interpretation of the data, drafting
and revising the manuscript. Rati Choksi: obtaining the data. Robert
Bucelli: obtaining and interpretation of the data, revising the manuscript.
Alan Pestronk: study design, obtaining, analysis, and interpretation of the
data, revising the manuscript.
STUDY FUNDING
No targeted funding reported.
DISCLOSURE
A. Alshehri and R. Choksi report no disclosures. R. Bucelli received a
financial gift from a patient’s family for Parsonage-Turner research.
A. Pestronk is on the scientific advisory board for The Myositis Associ-
ation; holds patents and receives payments for TS-HDS antibody,
GALOP antibody, GM1 Ganglioside antibody, and Sulfatide antibody;
received speaker honoraria from Athena; is on the speakers’ bureau for
The Myositis Association; received research support from Genzyme,
Insmed, Knopp, Ultragenyx, ISIS, Sanofi, Cytokinetics, GSK, Biogen,
CSL Behring, NIH, Washington University Neuromuscular Research
Fund, CINRG Children’s Hospital Washington DC, and Muscular Dys-
trophy Association; holds stock in Johnson & Johnson; and receives
payments for antibody testing from Athena. Go to Neurology.org/nn
for full disclosure forms.
Received February 23, 2015. Accepted in final form May 1, 2015.
REFERENCES
1. Hoogendijk J, Amato A, Lecky B, et al. 119th ENMC
international workshop: trial design in adult idiopathic
inflammatory myopathies, with the exception of inclusion
body myositis, 10–12 October 2003, Naarden, The
Netherlands. Neuromuscul Disord 2004;14:337–345.
2. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-
specific autoantibodies: their clinical and pathogenic sig-
nificance in disease expression. Rheumatology (Oxford)
2009;48:607–612.
3. Pestronk A. Acquired immune and inflammatory myopa-
thies: pathologic classification. Curr Opin Rheumatol
2011;23:595–604.
4. Christopher-Stine L, Casciola-Rosen LA, Hong G,
Chung T, Corse AM, Mammen AL. A novel autoantibody
recognizing 200-kd and 100-kd proteins is associated with
an immune-mediated necrotizing myopathy. Arthritis
Rheum 2010;62:2757–2766.
5. Mammen AL, Chung T, Christopher-Stine L, et al. Auto-
antibodies against 3-hydroxy-3-methylglutarylcoenzyme a
reductase (HMGCR) in patients with statin-associated
autoimmune myopathy. Arthritis Rheum 2011;63:
713–721.
Neurology: Neuroimmunology & Neuroinflammation 7
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
6. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR
autoantibodies in European patients with autoimmune
necrotizing myopathies: inconstant exposure to statin.
Medicine (Baltimore) 2014;93:150–157.
7. Albayda J, Mammen AL. Is statin-induced myositis part of
the polymyositis disease spectrum? Curr Rheumatol Rep
2014;16:433.
8. Hamann PD, Cooper RG, McHugh NJ, Chinoy H.
Statin-induced necrotizing myositis—a discrete autoimmune
entity within the “statin-induced myopathy spectrum”.
Autoimmun Rev 2013;12:1177–1181.
9. Limaye V, Bundell C, Hollingsworth P, et al. Clinical and
genetic associations of autoantibodies to 3-hydroxy-3-
methyl-glutaryl-coenzyme a reductase in patients with
immune-mediated myositis and necrotizing myopathy.
Muscle Nerve Epub 2014 Dec 18.
10. Watanabe Y, Suzuki S, Nishimura H, et al. Statins and
myotoxic effects associated with anti-3-hydroxy-3-
methylglutaryl-coenzyme a reductase autoantibodies:
an observational study in Japan. Medicine (Baltimore)
2015;94:e416.
11. Rose MR; ENMC IBM Working Group. 188th ENMC
International Workshop: Inclusion Body Myositis, 2–4
December 2011, Naarden, The Netherlands. Neuromus-
cul Disord 2013;23:1044–1055.
12. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibod-
ies: pathology in perimysium and neighbouring muscle
fibres. J Neurol Neurosurg Psychiatry 2000;68:472–478.
13. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy
with antibodies to the signal recognition particle: clinical
and pathological features. J Neurol Neurosurg Psychiatry
2002;73:420–428.
14. Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-
hydroxy-3-methylglutaryl-coenzyme A reductase antibodies
in statin users, including those with self-limited musculo-
skeletal side effects. Arthritis Care Res (Hoboken) 2012;64:
269–272.
15. Mohassel P, Mammen AL. The spectrum of statin myop-
athy. Curr Opin Rheumatol 2013;25:747–752.
16. Drouot L, Allenbach Y, Jouen F, et al. Exploring necro-
tizing autoimmune myopathies with a novel immunoassay
for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase auto-
antibodies. Arthritis Res Ther 2014;16:R39.
17. Stenzel W, Preuße C, Allenbach Y, et al. Nuclear actin
aggregation is a hallmark of anti-synthetase syndrome-
induced dysimmune myopathy. Neurology 2015;84:
1346–1354.
18. Allenbach Y, Benveniste O. Acquired necrotizing myopa-
thies. Curr Opin Neurol 2013;26:554–560.
19. Cai C, Alshehri A, Choksi R, Pestronk A. Regional ischemic
immune myopathy: a paraneoplastic dermatomyopathy.
J Neuropathol Exp Neurol 2014;73:1126–1133.
20. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated
conditions and antibodies associated with sporadic inclusion
body myositis. Muscle Nerve 1998;21:115–117.
21. Dalakas MC, Illa I, Gallardo E, Juarez C. Inclusion
body myositis and paraproteinemia: incidence and
immunopathologic correlations. Ann Neurol 1997;41:
100–104.
22. Werner JL, Christopher-Stine L, Ghazarian SR, et al.
Antibody levels correlate with creatine kinase levels
and strength in anti-HMG-CoA reductase-associated
autoimmune myopathy. Arthritis Rheum 2012;64:
4087–4093.
8 Neurology: Neuroimmunology & Neuroinflammation
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/NXI.0000000000000124
2015;2; Neurol Neuroimmunol Neuroinflamm 
Ali Alshehri, Rati Choksi, Robert Bucelli, et al. 
Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology




including high resolution figures, can be found at:
References
 http://nn.neurology.org/content/2/4/e124.full.html##ref-list-1











its entirety can be found online at:




Information about ordering reprints can be found online:
2015 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
